Advances in Biological Functions and Clinical Studies of FGF21
Wei Lin,Tianlei Zhang,Yiyang Zhou,Jinyu Zheng,Zhenlang Lin
DOI: https://doi.org/10.2147/DMSO.S317096
2021-07-17
Abstract:Wei Lin, 1 Tianlei Zhang, 1 Yiyang Zhou, 2 Jinyu Zheng, 2 Zhenlang Lin 1 1 Department of Pediatrics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, People's Republic of China; 2 Wenzhou Medical University, Wenzhou, 325000, Zhejiang, People's Republic of China Correspondence: Zhenlang Lin Department of Pediatrics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, People's Republic of China Email Fibroblast growth factor 21 (FGF21) regulates many crucial biological processes in human and mammals, particularly metabolic modulation and protective effect after injury. Therefore, determining complex regulatory mechanisms and elucidating the signaling pathway may greatly promote the prevention, diagnosis, and treatment of related injury and metabolic diseases. This review focused on the metabolic modulation and protective effect of FGF21 and summarized the molecular mechanisms and clinical research developments. Keywords: fibroblast growth factor 21, molecular mechanisms, metabolic modulation, protective effect, clinical application Fibroblast growth factors (FGFs) are widely expressed in the human body and have numerous and complicated physiological functions. FGFs regulate cell growth, proliferation, differentiation, and metabolic modulation, tissue repair, and inflammatory response. 1 , 2 FGFs can be divided into three types (classic, intracellular and hormone-like types) based on their action modes. 3 Classic and intracellular FGFs mostly act in an autocrine or paracrine way, 4 while hormone-like FGFs mainly act in the endocrine way. 5 Most autocrine and paracrine FGFs have a high affinity for the heparin glucosamine sulfate (HSGAG), which promotes the binding of the FGFs to the tyrosine kinase FGF receptor (FGFR1-4) on the cell surface, inducing FGFR activation, dimerization, and activation of downstream signaling pathways. 6–9 HSGAGs can also stabilize FGFs, prevent FGFs degradation, and limit the diffusion range of FGFs. 10 FGF21 is a member of the FGF19 subfamily in the FGFs family and belongs to the hormone-like FGFs. Compared to other FGFs members, FGF21 has three special features: 1. It has no obvious mitogenic or tumor-promoting function; 11 2. The spatial configuration variation of the region that binds to HSGAGs makes it have a weaker affinity for HSGAG, thus not easily bound in the extracellular matrix. However, it enters the circulation in the form of endocrine hormones to regulate metabolism and cross the blood-brain barrier through simple diffusion; 12 3. It does not directly bind to cell receptors, and it needs β-Klotho protein to form a stable combination to play its physiological role. Herein, the latest research progress on FGF21 is summarized. Unlike the classical FGFs, FGF21 binds to FGF receptors (FGFRs) and the co-receptor protein β-Klotho (a single transmembrane protein expressed during the differentiation of adipose precursor cells into adipocytes). Besides, FGF21 activates the signal transduction downstream only when FGFRs and β-Klotho are dimerized and autophosphorylated. 13 , 14 Neither β-Klotho nor FGFRs can be activated by FGF21 alone. 15 In the FGF21-FGFRs-β-Klotho complex, β-Klotho, a "zip code"-like receptor, is the main high-affinity receptor of FGF21, providing the targeted signals for FGF21. At the same time, FGFR acts as a catalytic subunit that mediates receptor dimerization and intracellular signal transduction. 16 Studies have also shown that the C-terminus and N-terminus are involved in activating FGF21 receptors, and any deletion of the terminus greatly reduces FGF21 activity. The C-terminus of FGF21 has a sugar-mimicking Ser-pro-Ser motif, which can be recognized and bound by β-Klotho. Besides, the C-terminus mutation of FGF21 is associated with an affinity decrease of β-Klotho, indicating that the C-terminal also mediates the binding of FGF21 and β-Klotho. Although the N-terminal mutation of FGF21 is also associated with decreased activity, it can still bind to β-Klotho, suggesting that the N-terminal only participates in the receptor activation process. 16–19 Therefore, complete C-terminal and N-terminal structure and simultaneous binding to β-Klotho an -Abstract Truncated-